Request a Quote

News & Events

iSpecimen® Founder and CEO Chris Ianelli to Join Industry Panel at Molecular Med TRICON

Plenary session to feature emerging technologies and industry perspectives in molecular medicine

On March 13th, iSpecimen Founder and CEO Christopher Ianelli, MD, PhD, will appear on a panel of senior executives exploring hot technologies and topics in molecular medicine at Molecular Med TRI-CON in San Francisco.

The plenary session event, titled Emerging Technologies and Industry Perspectives, takes place Wednesday March 13 at 8:15 a.m. at the Moscone South Convention Center. Panelists will present individually prior to a moderated Q&A. Ianelli will describe the challenges of biospecimen procurement, its impact on medical progress, and iSpecimen’s role in addressing these problems.

Other panelists include:

  • Ardy Arianpour, CEO & Co-Founder, Seqster
  • Norman Packard, CEO, Daptics
  • Florian Bell, Senior Member, Technical Staff-System Integration, Qorvo Biotechnologies, LLC
  • Martha Najib, Vice President, Strategic Marketing Analyst, Ximedica
  • Trevor Johnson, CEO, Flagship Biosciences
  • Lauren Shields, PhD, Head, Customer Success, East, Benchling
  • Paul Smith, CEO, ANGLE Biosciences Inc.
  • Michael Fero, PhD, CEO, TeselaGen Biotechnology

The panel will be moderated by:

  • Kristin Ciriello Pothier, Global Head of Life Sciences Strategy, Parthenon-EY, and author of “Personalizing Precision Medicine”
  • Scott Palmer, Senior Vice President and Head of Precision Medicine, Parthenon-EY

iSpecimen Marketplace hands-on opportunity

Also at TRI-CON, iSpecimen will be demoing the iSpecimen Marketplace in BOOTH # 210. The marketplace isan online exchange that connects researchers with the human biospecimens they need for their work, and helps biorepositories advance their missions. Visitors will be able to search millions of biospecimens from the intuitive marketplace interface.

The 26th International Molecular Medicine Tri-Conference, or Molecular Med TRI-CON, brings together more than 3,700 drug discovery, drug development and diagnostics professionals discussing cancer research, big data, molecular diagnostics, precision medicine, rare diseases, data science, human microbiome, point-of-care diagnostics, infectious diseases and more. It runs March 10-15.